Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Sep;90(3):1093–1099. doi: 10.1172/JCI115925

Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.

P Nisticò 1, R Mortarini 1, L B De Monte 1, A Mazzocchi 1, M Mariani 1, F Malavasi 1, G Parmiani 1, P G Natali 1, A Anichini 1
PMCID: PMC329969  PMID: 1387883

Abstract

Intratumor heterogeneity for susceptibility to cytotoxic T lymphocytes (CTL)-mediated lysis represents a major obstacle to cancer adoptive immunotherapy. To overcome the heterogeneity observed in terms of susceptibility of target cells to cell-mediated lysis, in this study we used two purified bispecific monoclonal antibodies (bsmAbs) that recognize molecules expressed by cytotoxic effector cells (CD3 and IgG Fc receptorial molecules), as well as one high molecular weight melanoma-associated antigen (HMW-MAA). The ability of these reagents to enhance or induce a relevant in vitro cytotoxic activity by a CTL clone (CTL 49) isolated from PBL of a melanoma patient was tested on a large panel of autologous and allogeneic melanoma cell lines and clones. Functional studies revealed that the CTL 49 clone lysed all the HMW-MAA+ tumor lines in the presence of bsmAbs and that these reagents affected the target lysis in a cooperative fashion. The effectiveness of bsmAbs in overcoming the heterogeneous susceptibility of human melanoma cells to cell-mediated lysis may find practical implications in cancer adoptive immunotherapy.

Full text

PDF
1093

Images in this article

1095Image
on p.1095

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albino A. P., Le Strange R., Oliff A. I., Furth M. E., Old L. J. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature. 1984 Mar 1;308(5954):69–72. doi: 10.1038/308069a0. [DOI] [PubMed] [Google Scholar]
  2. Anichini A., Castelli C., Sozzi G., Fossati G., Parmiani G. Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. J Immunol. 1988 Jan 1;140(1):183–191. [PubMed] [Google Scholar]
  3. Anichini A., Fossati G., Parmiani G. Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones. J Exp Med. 1986 Jan 1;163(1):215–220. doi: 10.1084/jem.163.1.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Anichini A., Mazzocchi A., Fossati G., Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol. 1989 May 15;142(10):3692–3701. [PubMed] [Google Scholar]
  5. DeMonte L. B., Nistico P., Tecce R., Dellabona P., Momo M., Anichini A., Mariani M., Natali P. G., Malavasi F. Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies. Proc Natl Acad Sci U S A. 1990 Apr;87(8):2941–2945. doi: 10.1073/pnas.87.8.2941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Donohue J. H., Ramsey P. S., Kerr L. A., Segal D. M., McKean D. J. Enhanced in vitro lysis of human ovarian carcinomas with activated peripheral blood lymphocytes and bifunctional immune heteroaggregates. Cancer Res. 1990 Oct 15;50(20):6508–6514. [PubMed] [Google Scholar]
  7. Geppert T. D., Davis L. S., Gur H., Wacholtz M. C., Lipsky P. E. Accessory cell signals involved in T-cell activation. Immunol Rev. 1990 Oct;117:5–66. doi: 10.1111/j.1600-065x.1990.tb00566.x. [DOI] [PubMed] [Google Scholar]
  8. Giacomini P., Segatto O., Natali P. G. Multiple epitope recognition: an approach to improved radioimmunodetection of tumor-associated antigens. Int J Cancer. 1987 Jun 15;39(6):729–736. doi: 10.1002/ijc.2910390613. [DOI] [PubMed] [Google Scholar]
  9. Houghton A. N., Real F. X., Davis L. J., Cordon-Cardo C., Old L. J. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med. 1987 Mar 1;165(3):812–829. doi: 10.1084/jem.165.3.812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jung G., Eberhard H. J. An in-vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol Today. 1988 Sep;9(9):257–260. doi: 10.1016/0167-5699(88)91304-7. [DOI] [PubMed] [Google Scholar]
  11. Kerr L., Huntoon C., Donohue J., Leibson P. J., Bander N. H., Ghose T., Luner S. J., Vessella R., McKean D. J. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes. J Immunol. 1990 May 15;144(10):4060–4067. [PubMed] [Google Scholar]
  12. Lanzavecchia A., Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol. 1987 Jan;17(1):105–111. doi: 10.1002/eji.1830170118. [DOI] [PubMed] [Google Scholar]
  13. Malavasi F., Bellone G., Matera L., Milanese C., Ferrero E., Funaro A., Demaria S., Caligaris-Cappio F., Camussi G., Dellabona P. Murine monoclonal antibodies as probes for the phenotypical, functional, and molecular analysis of a discrete peripheral blood lymphocyte population exerting natural killer activity in vitro. Hum Immunol. 1985 Oct;14(2):87–102. doi: 10.1016/0198-8859(85)90067-9. [DOI] [PubMed] [Google Scholar]
  14. Malavasi F., Tetta C., Funaro A., Bellone G., Ferrero E., Franzone A. C., Dellabona P., Rusci R., Matera L., Camussi G. Fc receptor triggering induces expression of surface activation antigens and release of platelet-activating factor in large granular lymphocytes. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2443–2447. doi: 10.1073/pnas.83.8.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mazzocchi A., Anichini A., Castelli C., Sensi M., Poli F., Russo C., Parmiani G. T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: evidence with a single T cell clone. Cancer Immunol Immunother. 1990;32(1):13–21. doi: 10.1007/BF01741719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mezzanzanica D., Canevari S., Ménard S., Pupa S. M., Tagliabue E., Lanzavecchia A., Colnaghi M. I. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer. 1988 Apr 15;41(4):609–615. doi: 10.1002/ijc.2910410422. [DOI] [PubMed] [Google Scholar]
  17. Mortarini R., Belli F., Parmiani G., Anichini A. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. Int J Cancer. 1990 Feb 15;45(2):334–341. doi: 10.1002/ijc.2910450221. [DOI] [PubMed] [Google Scholar]
  18. Natali P. G., Cavaliere R., Bigotti A., Nicotra M. R., Russo C., Ng A. K., Giacomini P., Ferrone S. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol. 1983 Mar;130(3):1462–1466. [PubMed] [Google Scholar]
  19. Nelson H. Targeted cellular immunotherapy with bifunctional antibodies. Cancer Cells. 1991 May;3(5):163–172. [PubMed] [Google Scholar]
  20. Nisticò P., Tecce R., Giacomini P., Cavallari A., D'Agnano I., Fisher P. B., Natali P. G. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res. 1990 Dec 1;50(23):7422–7429. [PubMed] [Google Scholar]
  21. Parmiani G., Anichini A., Fossati G. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst. 1990 Mar 7;82(5):361–370. doi: 10.1093/jnci/82.5.361. [DOI] [PubMed] [Google Scholar]
  22. Perez P., Hoffman R. W., Titus J. A., Segal D. M. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J Exp Med. 1986 Jan 1;163(1):166–178. doi: 10.1084/jem.163.1.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Roosnek E., Lanzavecchia A. Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell. J Exp Med. 1989 Jul 1;170(1):297–302. doi: 10.1084/jem.170.1.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rosenberg S. A. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today. 1988 Feb;9(2):58–62. doi: 10.1016/0167-5699(88)91261-3. [DOI] [PubMed] [Google Scholar]
  25. Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  26. Segal D. M., Wunderlich J. R. Targeting of cytotoxic cells with heterocrosslinked antibodies. Cancer Invest. 1988;6(1):83–92. doi: 10.3109/07357908809077031. [DOI] [PubMed] [Google Scholar]
  27. Spagnoli G. C., Ausiello C., Palma C., Bellone G., Ippoliti G., Letarte M., Malavasi F. Functional effects of a monoclonal antibody directed against a distinct epitope on 4F2 molecular complex in human peripheral blood mononuclear cell activation. Cell Immunol. 1991 Aug;136(1):208–218. doi: 10.1016/0008-8749(91)90395-r. [DOI] [PubMed] [Google Scholar]
  28. Topalian S. L., Muul L. M., Solomon D., Rosenberg S. A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987 Aug 24;102(1):127–141. doi: 10.1016/s0022-1759(87)80018-2. [DOI] [PubMed] [Google Scholar]
  29. Van den Eynde B., Hainaut P., Hérin M., Knuth A., Lemoine C., Weynants P., van der Bruggen P., Fauchet R., Boon T. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer. 1989 Oct 15;44(4):634–640. doi: 10.1002/ijc.2910440413. [DOI] [PubMed] [Google Scholar]
  30. Weiss A. Structure and function of the T cell antigen receptor. J Clin Invest. 1990 Oct;86(4):1015–1022. doi: 10.1172/JCI114803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Zarcone D., Prasthofer E. F., Malavasi F., Pistoia V., LoBuglio A. F., Grossi C. E. Ultrastructural analysis of human natural killer cell activation. Blood. 1987 Jun;69(6):1725–1736. [PubMed] [Google Scholar]
  32. Ziai M. R., Imberti L., Nicotra M. R., Badaracco G., Segatto O., Natali P. G., Ferrone S. Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. Cancer Res. 1987 May 1;47(9):2474–2480. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES